Genprex (GNPX) Insider Trading & Ownership $1.10 -0.18 (-14.06%) (As of 11/20/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Genprex (NASDAQ:GNPX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.47%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$41,350.00Number OfInsiders Selling(Last 3 Years)0 Get GNPX Insider Trade Alerts Want to know when executives and insiders are buying or selling Genprex stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address GNPX Insider Buying and Selling by Quarter Ad Crypto 101 MediaDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! Genprex Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/21/2023Catherine M VaczyEVPBuy500$42.80$21,400.00 4/21/2023John Rodney VarnerCEOBuy475$42.00$19,950.00 (Data available from 1/1/2013 forward) GNPX Insider Trading Activity - Frequently Asked Questions Who is on Genprex's Insider Roster? The list of insiders at Genprex includes Catherine M Vaczy, and John Rodney Varner. Learn more on insiders at GNPX. What percentage of Genprex stock is owned by insiders? 8.47% of Genprex stock is owned by insiders. Learn more on GNPX's insider holdings. Which Genprex insiders have been buying company stock? The following insiders have purchased GNPX shares in the last 24 months: Catherine M Vaczy ($21,400.00), and John Rodney Varner ($19,950.00). How much insider buying is happening at Genprex? Insiders have purchased a total of 975 GNPX shares in the last 24 months for a total of $41,350.00 bought. Genprex Key ExecutivesDr. Mark S. Berger M.D. (Age 69)Chief Medical Officer Compensation: $528.16kMr. David M. SchlossSenior Vice President of Human ResourcesMr. Thomas C. Gallagher Esq.Senior Vice President of Intellectual Property & LicensingDr. Suzanne Thornton-JonesSenior Vice President of Regulatory Affairs & Quality More Insider Trading Tools from MarketBeat Related Companies NKGen Biotech Insider Ownership Indaptus Therapeutics Insider Ownership Turnstone Biologics Insider Ownership Kiora Pharmaceuticals Insider Ownership Mustang Bio Insider Ownership Imunon Insider Ownership Vincerx Pharma Insider Ownership Aytu BioPharma Insider Ownership Ensysce Biosciences Insider Ownership Conduit Pharmaceuticals Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:GNPX) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe smart-money is buying this US$1 lithium stockLithium is getting white-hot once again! And that means well-timed investors who position now in the best n...Resource Stock Digest | Sponsored31 Billionaires Are Loading Up on This SectorWhy are 31 of the world's richest billionaires, like Warren Buffett, Jeff Bezos, the Walton family, and Bill G...InvestorPlace | SponsoredFormer Trump advisor releases terrifying warningGoldman Sachs: 300 Million People Are At Risk The mainstream media are practically ignoring the most import...Wide Moat Research | SponsoredMy favorite credit card just increased its sign-up bonusTired of getting average credit card rewards? This credit card just increased its sign-up bonus to 75,000 bonu...Card Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
